Patient Condition
The patient began to experience mild memory loss in early 2023 and often forgot recent events and appointments. A comprehensive evaluation was performed at Mayo Clinic, with an MMSE score of 22 (mild cognitive impairment), cerebrospinal fluid examination showed a decrease in Aβ42, an increase in tau protein, and positive amyloid PET. Early Alzheimer's disease was diagnosed. The patient has a family history and her mother had AD.
Treatment Timeline
| Phase | Details | Date |
|---|
| Early and precise AD diagnosis | | |
| Gantenerumab subcutaneous injection therapy | | |
| Cognitive rehabilitation + comprehensive lifestyle intervention | | |
| Maintenance therapy and cognitive protection | | |
Treatment Outcome
| before | MMSE score of 22 points, mild cognitive impairment, mild decline in daily living activities, and significant decline in memory |
|---|
| after | MMSE score was 26 points (improvement by 4 points), cognitive function was stable, memory decline was significantly slowed down, and daily living skills were maintained well |
|---|
| highlight | Early intervention has significant effects, good clearance of amyloid, and stable cognitive function |
|---|